HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Impaired Glucose Tolerance

Conditions

Impaired Glucose Tolerance

Trial Timeline

Mar 29, 2021 → Jun 29, 2022

NCT ID

NCT04727580

About HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo

HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo is a phase 2 stage product being developed by Haisco Pharmaceutical Group for Impaired Glucose Tolerance. The current trial status is completed. This product is registered under clinical trial identifier NCT04727580. Target conditions include Impaired Glucose Tolerance.

What happened to similar drugs?

3 of 5 similar drugs in Impaired Glucose Tolerance were approved

Approved (3) Terminated (1) Active (2)

✅Exenatide + MetforminEli LillyApproved

✅Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeksGilead SciencesApproved

✅Gabapentin + Gabapentin + Gabapentin + GabapentinPfizerApproved

🔄balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg + dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozinAstraZenecaPhase 3

🔄Ramipril + RosiglitazonePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04727580	Phase 2	Completed	Mar 29, 2021	Jun 29, 2022	Impaired Glucose Tolerance

Competing Products

19 competing products in Impaired Glucose Tolerance

See all competitors

Product	Company	Stage	Hype Score
Aspirin + Alpha lipoic acid + Olmesartan + Placebo	Daiichi Sankyo	Pre-clinical	26
ASP8825	Astellas Pharma	Phase 1	29
ASP015K	Astellas Pharma	Phase 1	29
ASP015K	Astellas Pharma	Phase 1	29
Gilteritinib	Astellas Pharma	Phase 1	29
fospropofol + fospropofol + fospropofol + fospropofol	Eisai	Pre-clinical	18
Exenatide + Metformin	Eli Lilly	Approved	43
Apatinib Mesylate	Jiangsu Hengrui Medicine	Phase 1	25
balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg + dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin	AstraZeneca	Phase 3	47
Tetanus & Diphtheria booster vaccine (Td) + TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine] + Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)	Merck	Pre-clinical	26
ASA404	Novartis	Phase 1	21
MAS825 + Standard of Care (SoC)	Novartis	Phase 2	35
DFV890 + Standard of Care (SoC)	Novartis	Phase 2	35
Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeks	Gilead Sciences	Approved	43
Gabapentin + Gabapentin + Gabapentin + Gabapentin	Pfizer	Approved	35
Ramipril + Rosiglitazone	Pfizer	Phase 3	40
NBI-98854 50 mg capsule	Neurocrine Biosciences	Phase 1	26
BIS-001ER	Supernus Pharmaceuticals	Phase 1/2	30
GFT505 80mg + Placebo	Genfit	Phase 2	25